Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherLiab,goodWill,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,inventory,accountsPayable,capitalSurplus,otherCurrentLiab,retainedEarnings,treasuryStock,otherAssets,otherStockholderEquity,shortTermInvestments,deferredLongTermAssetCharges,shortLongTermDebt,changeToLiabilities,investments,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,INCY,2618745000.0,219923008,,,171633000,,149456000,168859000,314327000,145468000,145468000,,-358000,,,,22177000,705709000,560241000,391382000,26165000,,149456000,149456000,161523000.0,968762000.0,2935861000.0,3904623000.0,2935861000.0,259000000.0,155593000.0,2080967000.0,675516000.0,689043000.0,2677773000.0,220691000.0,438170000.0,52260000.0,675516000.0,,,,,,,,,,0.0,,,,,,,,,,,,,,,,2002257000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,us_market,USD,-0.04598421,0,PRE,NMS,False,False,77.03,1630526402,0.5400009,76.71,80.3,76.13,2662261,17.117777,6.209092,15,America/New_York,EDT,2,0.70597583,76.13 - 80.3,76.49,0.0,0.0,8,8,finmb_332954,NasdaqGS,Incyte Corporation,USD,1202279,757214,5.119995,0.07120004,71.91 - 101.47,-24.440002,-0.24085939,71.91,101.47,1620131400,1635926400,1636372800,35.31866,2.181,4.5,3.05,25.255737,-14400000,12.406,76.49743,0.5325699,0.006961932,80.7429,-3.7128983,16940668928,Incyte Corporation,0.8,,,101.47,71.91,76.5,80.74,1.2M,757.21k,219.92M,,186.3M,1.46%,93.85%,5.86M,4.63,3.80%,2.67%,5.16M,,,,,,0.00%,,,2:1,"Aug 31, 2000","Dec 30, 2020","Jun 29, 2021",12.41%,15.77%,7.54%,12.79%,2.72B,12.40,2.60%,276.63M,485.19M,337.64M,2.18,-48.50%,2.08B,9.45,34.25M,1.17,3.96,12.41,,,Value,19803,Healthcare,1773,9,3,"Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naÃ¯ve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.",Wilmington,302 498 6700,DE,5,1609372800,1625097600,8,United States,http://www.incyte.com,86400,8,1801 Augustine Cut-Off,Biotechnology
t-1,INCY,2405344000.0,219923008,,,69322000,,53535000,154144000,258118000,103974000,103974000,,-359000,,,,15787000,604718000,500744000,346600000,-34652000,,53535000,53535000,166907000.0,933592000.0,2727844000.0,3661436000.0,220000.0,264364000.0,155593000.0,1669968000.0,623881000.0,622657000.0,2449969000.0,202174000.0,397357000.0,16700000.0,85058000.0,4420902000.0,137850000.0,-1672920000.0,-20358000.0,64136000.0,-20358000.0,292425000.0,,,-13709000.0,-11670000.0,-59753000.0,-573000.0,12835000.0,-13015000.0,20028000.0,156846000.0,-2331000.0,206095000.0,13838000.0,-4406000.0,84637000.0,-6620000.0,85215000.0,-48083000.0,1826088000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,us_market,USD,-0.04598421,0,PRE,NMS,False,False,77.03,1630526402,0.5400009,76.71,80.3,76.13,2662261,17.117777,6.209092,15,America/New_York,EDT,2,0.70597583,76.13 - 80.3,76.49,0.0,0.0,8,8,finmb_332954,NasdaqGS,Incyte Corporation,USD,1202279,757214,5.119995,0.07120004,71.91 - 101.47,-24.440002,-0.24085939,71.91,101.47,1620131400,1635926400,1636372800,35.31866,2.181,4.5,3.05,25.255737,-14400000,12.406,76.49743,0.5325699,0.006961932,80.7429,-3.7128983,16940668928,Incyte Corporation,0.8,,,101.47,71.91,76.5,80.74,1.2M,757.21k,219.92M,,186.3M,1.46%,93.85%,5.86M,4.63,3.80%,2.67%,5.16M,,,,,,0.00%,,,2:1,"Aug 31, 2000","Dec 30, 2020","Jun 29, 2021",12.41%,15.77%,7.54%,12.79%,2.72B,12.40,2.60%,276.63M,485.19M,337.64M,2.18,-48.50%,2.08B,9.45,34.25M,1.17,3.96,12.41,,,Value,19803,Healthcare,1773,9,3,"Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naÃ¯ve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.",Wilmington,302 498 6700,DE,5,1609372800,1625097600,8,United States,http://www.incyte.com,86400,8,1801 Augustine Cut-Off,Biotechnology
t-2,INCY,2283384000.0,219923008,,,168102000,,149850000,167228000,334812000,167584000,167584000,,-428000,,,,18252000,789509000,621925000,454697000,518000,,149850000,149850000,172291000.0,949650000.0,2611268000.0,3560918000.0,219000.0,271694000.0,155593000.0,1513008000.0,631195000.0,588076000.0,2359894000.0,222301000.0,481994000.0,16425000.0,98767000.0,4352864000.0,109018000.0,-1726455000.0,-15360000.0,62763000.0,-15360000.0,288369000.0,2054000.0,,-23745000.0,-51297000.0,-102730000.0,-217000.0,11872000.0,54980000.0,18709000.0,14327000.0,-2136000.0,107321000.0,15666000.0,-10264000.0,-117529000.0,-6620000.0,38263000.0,-51433000.0,1728699000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,us_market,USD,-0.04598421,0,PRE,NMS,False,False,77.03,1630526402,0.5400009,76.71,80.3,76.13,2662261,17.117777,6.209092,15,America/New_York,EDT,2,0.70597583,76.13 - 80.3,76.49,0.0,0.0,8,8,finmb_332954,NasdaqGS,Incyte Corporation,USD,1202279,757214,5.119995,0.07120004,71.91 - 101.47,-24.440002,-0.24085939,71.91,101.47,1620131400,1635926400,1636372800,35.31866,2.181,4.5,3.05,25.255737,-14400000,12.406,76.49743,0.5325699,0.006961932,80.7429,-3.7128983,16940668928,Incyte Corporation,0.8,,,101.47,71.91,76.5,80.74,1.2M,757.21k,219.92M,,186.3M,1.46%,93.85%,5.86M,4.63,3.80%,2.67%,5.16M,,,,,,0.00%,,,2:1,"Aug 31, 2000","Dec 30, 2020","Jun 29, 2021",12.41%,15.77%,7.54%,12.79%,2.72B,12.40,2.60%,276.63M,485.19M,337.64M,2.18,-48.50%,2.08B,9.45,34.25M,1.17,3.96,12.41,,,Value,19803,Healthcare,1773,9,3,"Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naÃ¯ve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.",Wilmington,302 498 6700,DE,5,1609372800,1625097600,8,United States,http://www.incyte.com,86400,8,1801 Augustine Cut-Off,Biotechnology
t-3,INCY,2057565000.0,219923008,,,-3508000,,-15203000,121025000,133223000,12198000,12198000,,-544000,,,,11695000,620643000,608445000,487420000,-15706000,,-15203000,-15203000,177675000.0,916597000.0,2390833000.0,3307430000.0,219000.0,264123000.0,155593000.0,1497775000.0,606202000.0,527458000.0,2159425000.0,222810000.0,356182000.0,17012000.0,122512000.0,4276667000.0,101442000.0,-1876305000.0,-9748000.0,64469000.0,-9748000.0,237025000.0,,11900000.0,31603000.0,38368000.0,-14453000.0,-232000.0,931000.0,24271000.0,7783000.0,171125000.0,2532000.0,182115000.0,12749000.0,180000.0,64068000.0,-6620000.0,64247000.0,-52821000.0,1553223000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,us_market,USD,-0.04598421,0,PRE,NMS,False,False,77.03,1630526402,0.5400009,76.71,80.3,76.13,2662261,17.117777,6.209092,15,America/New_York,EDT,2,0.70597583,76.13 - 80.3,76.49,0.0,0.0,8,8,finmb_332954,NasdaqGS,Incyte Corporation,USD,1202279,757214,5.119995,0.07120004,71.91 - 101.47,-24.440002,-0.24085939,71.91,101.47,1620131400,1635926400,1636372800,35.31866,2.181,4.5,3.05,25.255737,-14400000,12.406,76.49743,0.5325699,0.006961932,80.7429,-3.7128983,16940668928,Incyte Corporation,0.8,,,101.47,71.91,76.5,80.74,1.2M,757.21k,219.92M,,186.3M,1.46%,93.85%,5.86M,4.63,3.80%,2.67%,5.16M,,,,,,0.00%,,,2:1,"Aug 31, 2000","Dec 30, 2020","Jun 29, 2021",12.41%,15.77%,7.54%,12.79%,2.72B,12.40,2.60%,276.63M,485.19M,337.64M,2.18,-48.50%,2.08B,9.45,34.25M,1.17,3.96,12.41,,,Value,19803,Healthcare,1773,9,3,"Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naÃ¯ve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.",Wilmington,302 498 6700,DE,5,1609372800,1625097600,8,United States,http://www.incyte.com,86400,8,1801 Augustine Cut-Off,Biotechnology
